



## Aldeyra Therapeutics to Present at the 38th Annual Canaccord Genuity Growth Conference

August 1, 2018

LEXINGTON, Mass., Aug. 1, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced that Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra, will present at the 38th Annual Canaccord Genuity Growth Conference on Wednesday, August 8, 2018 at 10:00 AM ET at the InterContinental Hotel, Boston, MA.

### ***About Aldeyra Therapeutics***

Aldeyra Therapeutics is developing next-generation medicines to improve the lives of patients with immune-mediated diseases. Aldeyra's lead product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and other forms of ocular inflammation. The company is also developing other product candidates for autoimmune and metabolic diseases. None of Aldeyra's product candidates have been approved for sale in the U.S. or elsewhere.

#### Corporate Contact:

David McMullin  
Aldeyra Therapeutics, Inc.  
Tel: 781-761-4904 ext. 218  
[dmcullin@aldeyra.com](mailto:dmcullin@aldeyra.com)

#### Investor Contact:

Chris Brinzey  
Westwicke Partners  
Tel: 339-970-2843  
[Chris.brinzey@westwicke.com](mailto:Chris.brinzey@westwicke.com)

#### Media Contact:

Cammy Duong  
MacDougall Biomedical Communications  
781-591-3443  
[cduong@macbiocom.com](mailto:cduong@macbiocom.com)

 View original content: <http://www.prnewswire.com/news-releases/aldeyra-therapeutics-to-present-at-the-38th-annual-canaccord-genuity-growth-conference-300689805.html>

SOURCE Aldeyra Therapeutics, Inc.